Navigation Links
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
Date:6/23/2008

dosing options when tesetaxel is used alone or in combination with other anticancer drugs. Preclinically, tesetaxel has demonstrated substantially higher activity against cell lines that were resistant to paclitaxel and docetaxel, since acquired resistance is not mediated by the multidrug-resistant p-glycoprotein.

As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with other taxanes. Moreover, unlike other oral taxanes that are currently in clinical development, nerve damage has not been a prominent side effect of tesetaxel. Thus, the drug offers substantial opportunities to improve patient convenience, safety, and anticancer activity.

More than 250 patients worldwide have been treated with oral tesetaxel in Phase I and Phase 2 clinical trials. The major side-effect of tesetaxel in clinical trials has been myelosuppression, chiefly neutropenia. Due to the occurrence of severe neutropenia that led to fatal outcomes in several patients with advanced cancer, the drug was placed on clinical hold by FDA. Resumption of clinical trials was subject to the lifting of this clinical hold.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
2. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
3. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
4. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
5. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
6. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals ... with KX2-361 at Roswell Park Cancer Institute. ... molecule drug that has shown potent inhibitory activity against ... those that are resistant to Temozolomide (T98G), the most ... In a well-established brain tumor mouse model, KX2-361 consistently ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... MOUNTAIN VIEW, Calif., Nov. 11 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Lazard Capital Markets 6th Annual Healthcare Conference on ... York City. , A live webcast of the presentation ... Pharmaceuticals, website at http://www.mappharma.com . A replay will also ...
... Finland, November 11 , ... be issued by the Finnish,Breast Cancer Group on Wednesday 11 November ... III Randomised Study in Women With Early Breast,Cancer Shows that Adding ... to Live Cancer-Free for Longer , An ...
Cached Medicine Technology:Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 2Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... May 2008] Golf can be a good investment for the ... university Karolinska Institutet. The death rate for golfers is 40 ... sex, age and socioeconomic status, which correspond to a 5 ... are the safest. , It is a well-known fact ...
... Results from a pivotal Phase III clinical ... once-daily, investigational anticoagulant medication, was superior in preventing ... knee replacement (TKR) surgery. The head-to-head study compared ... the current standard of care. , Data from ...
... PRINCETON JUNCTION, N.J., May 30 Lutronic, Inc., ... medical laser systems,announced today that its MOSAIC eCO2 ... fractional technology with the deep,ablative features of a ... FDA review and,clearance., With intuitive touch-screen software, ...
... options, TORONTO, May 30 /PRNewswire-FirstCall/ - Predictive ... announced it has been notified by,the American Stock ... to,support PreMD,s plan for regaining compliance with the ... the Company,s common stock from the,Exchange by filing ...
... than white women to receive the radiation therapy routinely ... a study that Dana-Farber Cancer Institute researchers will present ... Clinical Oncology in Chicago. , Although the disparity in ... of black and Hispanic breast cancer patients may be ...
... Medical researchers at The Ohio State University, in ... million grant from the National Institutes of Health to ... that help identify and advance treatments for patients. The ... Ohio State. , The Ohio State University Center for ...
Cached Medicine News:Health News:Golf prolongs life 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: